retatrutide and skin sensitivity Why may cause sensitivity: possible mechanisms Retatrutide skin sensitivity/allodynia around hair

13 The first four trials were designed primarily to assess cardiovascular safety in patients with T2D and yielded unexpected beneficial results

The current understanding, shaped largely by tirzepatide research, is more nuanced GIPR activation appears synergistic with GLP-1R activation in contexts where single-receptor work predicted a smaller signal

They add no value

Water for Injections BP Summary of Product Characteristics (SmPC)

E.TolhurstG.HabibA

However, these results must be contextualised carefully: Phase 2 trials are not powered to detect cardiovascular outcomes such as myocardial infarction, stroke, or cardiovascular mortality No dedicated cardiovascular outcome trial (CVOT) data exist for retatrutide such trials are required before definitive conclusions about cardiovascular benefit or risk can be drawn